title: [Antiviral effects of the combination of glycyrrhizin and ribavirin against influenza A H1N1 virus infection in vivo].
abstract: Ribavirin is a broad-spectrum antiviral agent and glycyrrhizin has activities of anti-inflammation, immunoregulation and anti-viral infections. To enhance antiviral efficacy and weaken side-effects of ribavirin, antiviral effects of the combination of glycyrrhizin and ribavirin were studied in the present study. Firstly, a mouse model of viral pneumonia was established by inoculation of influenza H1N1 virus. Protective effects of glycyrrhizin and ribavirin used alone or in combination against H1N1 virus infection in mice were evaluated based on the survival rate, lung index and virus titer in lungs of mice. Results showed that the combination of glycyrrhizin and ribavirin significantly inhibited the lung consolidation with a 36% inhibition ratio on the lung swell of infected mice. The combination of the two drugs exhibited synergetic effects on survival of infected mice. The combination of 50 mg · kg(-1) · d(-1) glycyrrhizin and 40 mg · kg(-1) · d(-1) ribavirin resulted a 100% protection for infected mice with a synergetic value of 36, which was significantly higher than the control group and each drug alone. This combination also resulted a significant drop of lung virus titer (P < 0.01), as well as inhibition on the production of proinflammatory cytokines IL-6 (P < 0.01), TNF-α (P < 0.01) and IL-1β (P < 0.05) induced by virus infection compared to the control. The treatment of ribavirin plus glycyrrhizin was more effective in influenza A infection in mice than either compound used alone, which suggested a potential clinical value of the combination of the two agents.
authors.forename: Xiu-xiu
authors.initials: XX
authors.lastname: Chen
authors.forename: Hong-xia
authors.initials: HX
authors.lastname: Zhou
authors.forename: Wen-bao
authors.initials: WB
authors.lastname: Qi
authors.forename: Zhang-yong
authors.initials: ZY
authors.lastname: Ning
authors.forename: Yong-jiang
authors.initials: YJ
authors.lastname: Ma
authors.forename: Yao-lan
authors.initials: YL
authors.lastname: Li
authors.forename: Guo-cai
authors.initials: GC
authors.lastname: Wang
authors.forename: Jian-xin
authors.initials: JX
authors.lastname: Chen
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D019695:Glycyrrhizic Acid / Q000494:pharmacology*; D007249:Inflammation / Q000276:immunology; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects*; D053583:Interleukin-1beta / Q000276:immunology; D015850:Interleukin-6 / Q000276:immunology; D008168:Lung / Q000276:immunology / Q000821:virology; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000188:drug therapy*; D011024:Pneumonia, Viral / Q000188:drug therapy; D012254:Ribavirin / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D000998:Antiviral Agents; C587672:IL1B protein, mouse; D053583:Interleukin-1beta; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D012254:Ribavirin; D019695:Glycyrrhizic Acid